TY  - THES
N2  - Lutathera is a radiopharmaceutical used to treat gastroenteropancreatic-neuroendocrine tumors(GEP-NETs) in adults that are positive for hormone receptor somatostatin. The cur-rent FDA-approved label describes Lutathera treatment as four 200 mCi cycles given every eight weeks. If the patient reacted negatively to toxicity caused by acute myelosuppression which is a decrease in bone marrow activity which leads to fewer red blood cells, white blood cells, and platelets, or nephrotoxicity(1), the dose is halved to 100 mCi. If the patient continues to experience toxicity from the radiopharmaceutical, the treatment is stopped. A dosimetry protocol will outline the imaging modality utilized to obtain quantitative infor-mation about the distribution of Lutathera, the frequency at which imaging needs to occur, and the time after injection that imaging needs to occur. Personalized dosimetry would also allow for an increase of prescribed activity with the gain in knowledge of the proximity to dose thresholds leading to deterministic effects for organs at risk.
DO  - 10.6083/pz50gw80v
DO  - DOI
AB  - Lutathera is a radiopharmaceutical used to treat gastroenteropancreatic-neuroendocrine tumors(GEP-NETs) in adults that are positive for hormone receptor somatostatin. The cur-rent FDA-approved label describes Lutathera treatment as four 200 mCi cycles given every eight weeks. If the patient reacted negatively to toxicity caused by acute myelosuppression which is a decrease in bone marrow activity which leads to fewer red blood cells, white blood cells, and platelets, or nephrotoxicity(1), the dose is halved to 100 mCi. If the patient continues to experience toxicity from the radiopharmaceutical, the treatment is stopped. A dosimetry protocol will outline the imaging modality utilized to obtain quantitative infor-mation about the distribution of Lutathera, the frequency at which imaging needs to occur, and the time after injection that imaging needs to occur. Personalized dosimetry would also allow for an increase of prescribed activity with the gain in knowledge of the proximity to dose thresholds leading to deterministic effects for organs at risk.
T1  - Evaluation and implementation of a dosimetry protocol for Lutetium Lu 177 DOTATATE for the treatment of gastroenteropancreatic-neuroendocrine tumors
DA  - 2022
AU  - Stoller, Jared
L1  - https://digitalcollections.ohsu.edu/record/9737/files/Stoller.Jared.2022.pdf
PB  - Oregon Health and Science University
PY  - 2022
ID  - 9737
L4  - https://digitalcollections.ohsu.edu/record/9737/files/Stoller.Jared.2022.pdf
KW  - Radiopharmaceuticals
KW  - Radiometry
KW  - Nuclear Medicine
TI  - Evaluation and implementation of a dosimetry protocol for Lutetium Lu 177 DOTATATE for the treatment of gastroenteropancreatic-neuroendocrine tumors
Y1  - 2022
L2  - https://digitalcollections.ohsu.edu/record/9737/files/Stoller.Jared.2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9737/files/Stoller.Jared.2022.pdf
UR  - https://digitalcollections.ohsu.edu/record/9737/files/Stoller.Jared.2022.pdf
ER  -